If you're looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here's why these blue chip ASX 200 shares are highly rated right now:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to look at is CSL. It is a leading biotechnology company behind the CSL Behring and Seqirus businesses.
These two businesses have a portfolio of life-saving and lucrative therapies and vaccines which save millions of lives and generate billions of dollars in sales each year.
But management isn't resting on its laurels. It continues to invest in the region of 10% to 11% of its sales into research and development activities. This means it has a development pipeline filled to the brim with important and potentially lucrative therapies.
Furthermore, CSL is in the process of making a major acquisition. It is aiming to acquire Vifor Pharma later this year, which will add key renal therapies to its portfolio and development pipeline.
Citi is a fan and has a buy rating and $335.00 price target on CSL's shares. Its analysts note that the "latest data points to continued improvement in plasma collection and strong underlying demand."
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of in-demand properties with exposure to key growth markets such as ecommerce.
Goodman has continued to experience strong demand for its properties in FY 2022. This has led to strong rental growth and a sky high occupancy rate.
In light of this strong form, management has just upgraded its earnings guidance again. It is now expecting its earnings per share to grow 23% in FY 2022.
The team at Goldman Sachs expect this solid form to continue. The broker highlights that "GMG offers an estimated FY22-24e earnings CAGR of ~13%, screening more favourably on a growth adjusted basis relative to the coverage average of ~8%."
As a result of this positive outlook, this week the broker has a reiterated its buy rating with an improved price target of $25.40.
